OptiMedica Corporation Awarded French Tender for Five Catalys® Precision Laser Systems; Platform to be Used in Multi-Center, 2,000-Eye, Randomized Clinical Study

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SUNNYVALE, Calif.--(BUSINESS WIRE)--OptiMedica Corp. has announced that it has been awarded a tender for five Catalys Precision Laser Systems for use in a French multi-center randomized clinical study sponsored by Centre Hospitalier Universitaire (CHU) de Bordeaux, France. Financed by the French Ministry of Health, the project will compare the efficacy and cost-effectiveness of laser cataract surgery versus manual cataract surgery in 2,000 eyes at five leading academic centers.1 “We thank the French research coordinators for choosing Catalys for this important study,” said Mark J. Forchette, chief executive officer, OptiMedica. “We are confident that patients and surgeons will benefit from the exceptional performance that Catalys has been shown to deliver, and we look forward to working closely with each center to ensure the success of this project.”

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC